Journal
CANCERS
Volume 10, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/cancers10100342
Keywords
trastuzumab; pertuzumab; breast cancer; HER2; HER family receptors; mechanisms; synergism
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Women and Children's Health Research Institute (WCHRI)
Ask authors/readers for more resources
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20-30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatment is still low. Continued research and development of novel agents and strategies of drug combinations is needed. A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer. This review examined and analyzed findings and hypotheses regarding the action and synergism of trastuzumab and pertuzumab and proposed a model of synergism based on available information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available